Deeper Knowledge, Faster

  • Anticipate your formulary budget
  • Find suppliers and generic API sources
  • Drug patents and clinical trials in dozens of countries

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Argus Health
Cantor Fitzgerald
US Department of Justice

Generated: June 22, 2017

DrugPatentWatch Database Preview

ORAPRED Drug Profile

« Back to Dashboard

Which patents cover Orapred, and what generic Orapred alternatives are available?

Orapred is a drug marketed by Concordia Pharms Inc and is included in two NDAs. There is one patent protecting this drug and one Paragraph IV challenge.

The generic ingredient in ORAPRED is prednisolone sodium phosphate. There are eighty-five drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the prednisolone sodium phosphate profile page.

Summary for Tradename: ORAPRED

Bulk Api Vendors: see list51
Clinical Trials: see list1
Patent Applications: see list3,578
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ORAPRED at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Concordia Pharms Inc
prednisolone sodium phosphate
SOLUTION;ORAL075117-001Dec 14, 2000DISCNNoNo► Subscribe► Subscribe
Concordia Pharms Inc
prednisolone sodium phosphate
TABLET, ORALLY DISINTEGRATING;ORAL021959-003Jun 1, 2006ABRXYesYes6,740,341► SubscribeY ► Subscribe
Concordia Pharms Inc
prednisolone sodium phosphate
TABLET, ORALLY DISINTEGRATING;ORAL021959-001Jun 1, 2006ABRXYesNo6,740,341► SubscribeY ► Subscribe
Concordia Pharms Inc
prednisolone sodium phosphate
TABLET, ORALLY DISINTEGRATING;ORAL021959-002Jun 1, 2006ABRXYesNo6,740,341► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: ORAPRED

Drugname Dosage Strength RLD Submissiondate
prednisolone sodium phosphateOrally Disintegrating Tablets10 mg, 15 mg and 30 mgOrapred7/22/2010
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Harvard Business School
Johnson and Johnson
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus